A Study to Evaluate Infants With Potential Exposure to Tanezumab Before Birth

Completed

Conditions studied: Infant Developmental Assessment

In brief

This study will examine post-natal neurologic and cognitive development of infants who may have been exposed to tanezumab or comparator in-utero during the tanezumab clinical program (whether the exposure is through maternal or paternal participation in a tanezumab clinical study).

Key facts

Study ID

NCT01362660

Run by

Pfizer

People needed

7

Starts

2011-06-01

Expected to finish

2012-06-01

Last updated by the study team

2013-02-06

Who can join

Age: any, up to 1. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subject is an infant born to a mother who was exposed to study drug on a tanezumab clinical study through direct maternal exposure; or is an infant born to a mother who is a partner of a male patient who was exposed to study drug in a tanezumab clinical study prior to or around the time of conception and/or is exposed during his partner's pregnancy.

You may not qualify if…

• There are no exclusion criteria for this study

Where it is running

• Pfizer Investigational Site — Tempe, Arizona, United States
• Pfizer Investigational Site — Tempe, Arizona, United States
• Pfizer Investigational Site — Wildomar, California, United States
• Pfizer Investigational Site — Cutler Bay, Florida, United States
• Pfizer Investigational Site — Duncansville, Pennsylvania, United States
• Pfizer Investigational Site — Memphis, Tennessee, United States
• Pfizer Investigational Site — Houston, Texas, United States
• Pfizer Investigational Site — Salt Lake City, Utah, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.